NeuroMetrix (NasdaqCM:NURO) - Share price, News & Analysis

NURO fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

NURO Stock Overview

Risk Analysis

Highly volatile share price over the past 3 months

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($29M)

NeuroMetrix Competitors

Natus Medical

NasdaqGS:NTUS

US$1.1b

Price History & Performance

Summary of all time highs, changes and price drops for NeuroMetrix
Historical stock prices
Current Share Price	US$4.10
52 Week High	US$38.75
52 Week Low	US$2.70
Beta	2.86
1 Month Change	30.99%
3 Month Change	-5.31%
1 Year Change	40.41%
3 Year Change	-29.31%
5 Year Change	-88.86%
Change since IPO	-100.00%

Recent News & Updates

May 11

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

	NURO	US Medical Equipment	US Market
7D	-4.9%	2.9%	6.2%
1Y	40.4%	-14.9%	-11.4%

Return vs Industry: NURO exceeded the US Medical Equipment industry which returned -14.9% over the past year.

Return vs Market: NURO exceeded the US Market which returned -10.2% over the past year.

Price Volatility

Is NURO's price volatile compared to industry and market?
NURO volatility
NURO Average Weekly Movement	25.5%
Medical Equipment Industry Average Movement	10.5%
Market Average Movement	7.8%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	2.8%

Stable Share Price: NURO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 25% a week.

Volatility Over Time: NURO's weekly volatility has decreased from 38% to 25% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1996	23	Shai Gozani	https://www.neurometrix.com

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.

NeuroMetrix Fundamentals Summary

How do NeuroMetrix's earnings and revenue compare to its market cap?
NURO fundamental statistics
Market Cap	US$28.72m
Earnings (TTM)	-US$3.18m
Revenue (TTM)	US$8.40m

3.4x

P/S Ratio

-9.0x

P/E Ratio

Is NURO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
NURO income statement (TTM)
Revenue	US$8.40m
Cost of Revenue	US$2.26m
Gross Profit	US$6.14m
Other Expenses	US$9.32m
Earnings	-US$3.18m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.45
Gross Margin	73.04%
Net Profit Margin	-37.86%
Debt/Equity Ratio	0%

How did NURO perform over the long term?

See historical performance and comparison

Valuation

Is NeuroMetrix undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

1.19x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NURO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NURO's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: NURO is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Medical Equipment industry average.

PE vs Market: NURO is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NURO's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: NURO is good value based on its Price-To-Book Ratio (1.2x) compared to the US Medical Equipment industry average (2.5x).

Future Growth

How is NeuroMetrix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

15.9%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroMetrix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has NeuroMetrix performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

57.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NURO is currently unprofitable.

Growing Profit Margin: NURO is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: NURO is unprofitable, but has reduced losses over the past 5 years at a rate of 57.8% per year.

Accelerating Growth: Unable to compare NURO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NURO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).

Return on Equity

High ROE: NURO has a negative Return on Equity (-13.12%), as it is currently unprofitable.

Financial Health

How is NeuroMetrix's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NURO's short term assets ($25.6M) exceed its short term liabilities ($1.7M).

Long Term Liabilities: NURO's short term assets ($25.6M) exceed its long term liabilities ($283.2K).

Debt to Equity History and Analysis

Debt Level: NURO is debt free.

Reducing Debt: NURO has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NURO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NURO has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 40.1% each year

Dividend

What is NeuroMetrix current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NURO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NURO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NURO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NURO's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NURO has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.8yrs

Average management tenure

CEO

Shai Gozani (56 yo)

25.92yrs

Tenure

US$557,656

Compensation

Dr. Shai N. Gozani, M.D., Ph D., founded Neurometrix Inc. in 1996 and has been its President since 2002 and Chief Executive Officer since 1997 and its Secretary July 2008. He has been the Chairman of the B...

CEO Compensation Analysis

Compensation vs Market: Shai's total compensation ($USD557.66K) is about average for companies of similar size in the US market ($USD759.98K).

Compensation vs Earnings: Shai's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: NURO's management team is seasoned and experienced (8.8 years average tenure).

Board Members

Experienced Board: NURO's board of directors are seasoned and experienced ( 11.2 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 84.2%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/28 00:00
End of Day Share Price	2022/05/27 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31